Form 4: Quest Diagnostics SVP Karthik Kuppusamy Reports Stock Transactions

Karthik Kuppusamy, SVP of Clinical Solutions at Quest Diagnostics, reports the acquisition and disposal of company stock, including dividend reinvestments and transactions within the company's stock purchase and 401(k) plans.

Summary

• Karthik Kuppusamy, SVP of Clinical Solutions at Quest Diagnostics, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On July 22, 2024, Kuppusamy acquired 31 shares of common stock through a dividend reinvestment plan at a price of $146.973 per share.
• Kuppusamy also disposed of 358 shares of common stock.
• Following these transactions, Kuppusamy directly owns 13,511 shares of Quest Diagnostics stock.
• Additionally, Kuppusamy indirectly owns 1,557 shares through the company's 401(k) plan.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment about the company's performance.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.
• It offers insights into executive compensation and stock ownership.

Key Dates